|
1
|
MacGregor JI and Jordan VC: Basic guide to
the mechanisms of antiestrogen action. Pharmacol Rev. 50:151–196.
1998.PubMed/NCBI
|
|
2
|
Sommer S and Fuqua SA: Estrogen receptor
and breast cancer. Semin Cancer Biol. 11:339–352. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Green S, Walter P, Greene G, et al:
Cloning of the human oestrogen receptor cDNA. J Steroid Biochem.
24:77–83. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kuiper GG, Enmark E, Pelto-Huikko M, et
al: Cloning of a novel receptor expressed in rat prostate and
ovary. Proc Natl Acad Sci USA. 93:5925–5930. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Katzenellenbogen BS, Montano MM, Ediger
TR, et al: Estrogen receptors: selective ligands, partners, and
distinctive pharmacology. Recent Prog Horm Res. 55:163–193.
2000.PubMed/NCBI
|
|
6
|
Nilsson S, Makela S, Treuter E, et al:
Mechanisms of estrogen action. Physiol Rev. 81:1535–1565. 2001.
|
|
7
|
Speirs V, Carder PJ, Lane S, et al:
Oestrogen receptor β: what it means for patients with breast
cancer. Lancet Oncol. 5:174–181. 2004.
|
|
8
|
Dahlman-Wright K, Cavailles V, Fuqua SA,
et al: International Union of Pharmacology. LXIV Estrogen
receptors. Pharmacol Rev. 58:773–781. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Harris HA: Estrogen receptor-β: recent
lessons from in vivo studies. Mol Endocrinol. 21:1–13. 2007.
|
|
10
|
Chen KH, Guo X, Ma D, et al: Dysregulation
of HSG triggers vascular proliferative disorders. Nat Cell Biol.
6:872–883. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Neuspiel M, Zunino R, Gangaraju S, et al:
Activated mitofusin 2 signals mitochondrial fusion, interferes with
Bax activation, and reduces susceptibility to radical induced
depolarization. J Biol Chem. 280:25060–25070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Santel A, Frank S, Gaume B, et al:
Mitofusin-1 protein is a generally expressed mediator of
mitochondrial fusion in mammalian cells. J Cell Sci. 116:2763–2774.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sugioka R, Shimizu S and Tsujimoto Y:
Fzo1, a protein involved in mitochondrial fusion, inhibits
apoptosis. J Biol Chem. 279:52726–52734. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
DeNardo DG, Kim HT, Hilsenbeck S, et al:
Global gene expression analysis of estrogen receptor transcription
factor cross talk in breast cancer: identification of
estrogen-induced/activator protein-1-dependent genes. Molecular
Endocrinology. 19:362–378. 2005. View Article : Google Scholar
|
|
15
|
Ma L, Liu YP, Geng CZ, et al: Low-dose
epirubicin inhibits ezrin-mediated metastatic behavior of breast
cancer cells. Tumori. 97:400–405. 2011.PubMed/NCBI
|
|
16
|
Ström A, Hartman J, Foster JS, et al:
Estrogen receptor beta inhibits 17beta-estradiol-stimulated
proliferation of the breast cancer cell line T47D. Proc Natl Acad
Sci USA. 101:1566–1571. 2004.PubMed/NCBI
|
|
17
|
Secreto FJ, Monroe DG, Dutta S, et al:
Estrogen receptor alpha/beta isoforms, but not betacx, modulate
unique patterns of gene expression and cell proliferation in Hs578T
cells. J Cell Biochem. 101:1125–1147. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen L, Qiu J, Yang C, et al:
Identification of a novel estrogen receptor beta1 binding partner,
inhibitor of differentiation-1, and role of ERbeta1 in human breast
cancer cells. Cancer Lett. 278:210–219. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jensen EV, Cheng G, Palmieri C, et al:
Estrogen receptors and proliferation markers in primary and
recurrent breast cancer. Proc Natl Acad Sci USA. 4:42001.PubMed/NCBI
|
|
20
|
Speirs V, Malone C, Walton DS, et al:
Increased expression of estrogen receptor β mRNA in
tamoxifen-resistant breast cancer patients. Cancer Res.
59:5421–5424. 1999.
|
|
21
|
Kushner PJ, Agard DA, Greene GL, et al:
Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol.
74:311–317. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang W, Dong L, Saville B, et al:
Transcriptional activation of E2F1 gene expression by 17β-estradiol
in MCF-7 cells is regulated by NF-Y-Sp1/estrogen receptor
interactions. Mol Endocrinol. 13:1373–1387. 1999.
|
|
23
|
Safe S: Transcriptional activation of
genes by 17β-estradiol through estrogen receptor-Sp1 interactions.
Vitam Horm. 62:231–252. 2001.
|
|
24
|
Ru Lee W, Chen CC, Liu S, et al: 17
beta-estradiol (E2) induces cdc25A gene expression in breast cancer
cells by genomic and non-genomic pathways. J Cell Biochem.
99:209–220. 2006.PubMed/NCBI
|
|
25
|
Yoshioka H, Hiromori Y, Aoki A, et al:
Possible aryl hydrocarbon receptor-independent pathway of 2, 3, 7,
8-tetrachlorodibenzo-p-dioxin-induced antiproliferative response in
human breast cancer cells. Toxicol Lett. 211:257–265. 2012.
View Article : Google Scholar
|
|
26
|
Singh KP, Treas J, Tyagi T, et al: DNA
demethylation by 5-aza-2-deoxycytidine treatment abrogates 17
beta-estradiol-induced cell growth and restores expression of DNA
repair genes in human breast cancer cells. Cancer Lett. 316:62–69.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang W, Zhou D, Wei J, et al: Hepatitis B
virus X protein inhibits p53-mediated upregulation of mitofusin-2
in hepatocellular carcinoma cells. Biochem Biophys Res Commun.
421:355–360. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jin B, Fu G, Pan H, et al: Anti-tumour
efficacy of mitofusin-2 in urinary bladder carcinoma. Med Oncol.
28(Suppl 1): S373–S380. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rehman J, Zhang HJ, Toth PT, et al:
Inhibition of mitochondrial fission prevents cell cycle progression
in lung cancer. FASEB J. 26:2175–2186. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dotzlaw H, Leygue E, Watson PH, et al:
Expression of estrogen receptor-β in human breast tumors. J Clin
Endocrinol Metab. 82:2371–2374. 1997.
|
|
31
|
Fuqua SA, Schiff R, Parra I, et al:
Estrogen receptor β protein in human breast cancer: correlation
with clinical tumor parameters. Cancer Res. 63:2434–2439. 2003.
|
|
32
|
Pettersson K, Delaunay F and Gustafsson
JA: Estrogen receptor β acts as a dominant regulator of estrogen
signaling. Oncogene. 19:4970–4978. 2000.
|
|
33
|
Matthews J, Wihlen B, Tujague M, et al:
Estrogen receptor (ER) β modulates ER α-mediated transcriptional
activation by altering the recruitment of c-Fos and c-Jun to
estrogen-responsive promoters. Mol Endocrinol. 20:534–543.
2006.
|
|
34
|
Chang EC, Frasor J, Komm B, et al: Impact
of estrogen receptor β on gene networks regulated by estrogen
receptor α in breast cancer cells. Endocrinology. 147:4831–4842.
2006.
|
|
35
|
Lin CY, Strom A, Li Kong S, et al:
Inhibitory effects of estrogen receptor beta on specific
hormone-responsive gene expression and association with disease
outcome in primary breast cancer. Breast Cancer Res. 9:R252007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Williams C, Edvardsson K, Lewandowski SA,
et al: A genome-wide study of repressive effects of estrogen
receptor beta on estrogen receptor alpha signaling in breast cancer
cells. Oncogene. 27:1019–1032. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Paruthiyil S, Parmar H, Kerekatte V, et
al: Estrogen receptor β inhibits human breast cancer cell
proliferation and tumor formation by causing a G2 cell cycle
arrest. Cancer Res. 64:423–428. 2004.
|
|
38
|
Behrens D, Gill JH and Fichtner I: Loss of
tumourigenicity of stably ER β-transfected MCF-7 breast cancer
cells. Mol Cell Endocrinol. 274:19–29. 2007.PubMed/NCBI
|
|
39
|
Nadal-Serrano M, Sastre-Serra J, Pons DG,
et al: The ERalpha/ERbeta ratio determines oxidative stress in
breast cancer cell lines in response to 17beta-estradiol. J Cell
Biochem. 113:3178–3185. 2012. View Article : Google Scholar
|
|
40
|
Sastre-Serra J, Nadal-Serrano M, Pons DG,
et al: The effects of 17β-estradiol on mitochondrial biogenesis and
function in breast cancer cell lines are dependent on the ERα/ERβ
ratio. Cell Physiol Biochem. 29:261–268. 2012.
|
